UCB SA (UCB.BR)
EUR 187.45
(0.83%)
EUR 187.45
(0.83%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.03 Billion EUR | 13.67% |
| 2022 | 907 Million EUR | 3.3% |
| 2021 | 878 Million EUR | 2.81% |
| 2020 | 854 Million EUR | 9.49% |
| 2019 | 780 Million EUR | 20.56% |
| 2018 | 647 Million EUR | 8.38% |
| 2017 | 597 Million EUR | 3.29% |
| 2016 | 578 Million EUR | 2.12% |
| 2015 | 566 Million EUR | 3.47% |
| 2014 | 547 Million EUR | -12.76% |
| 2013 | 627 Million EUR | 1.79% |
| 2012 | 616 Million EUR | 14.71% |
| 2011 | 537 Million EUR | 23.73% |
| 2010 | 434 Million EUR | 7.16% |
| 2009 | 405 Million EUR | 11.57% |
| 2008 | 363 Million EUR | 18.24% |
| 2007 | 307 Million EUR | -28.94% |
| 2006 | 432 Million EUR | 65.52% |
| 2005 | 261 Million EUR | -30.78% |
| 2004 | 377.05 Million EUR | -6.66% |
| 2003 | 403.94 Million EUR | -47.77% |
| 2002 | 773.43 Million EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 1.13 Billion EUR | 0.0% |
| 2023 FY | 1.03 Billion EUR | 13.67% |
| 2023 Q2 | 912 Million EUR | 0.0% |
| 2023 Q4 | 1.03 Billion EUR | 0.0% |
| 2022 FY | 907 Million EUR | 3.3% |
| 2022 Q2 | 861 Million EUR | 0.0% |
| 2022 Q4 | 907 Million EUR | 0.0% |
| 2021 Q2 | 894 Million EUR | 0.0% |
| 2021 Q4 | 878 Million EUR | 0.0% |
| 2021 FY | 878 Million EUR | 2.81% |
| 2020 Q4 | 854 Million EUR | 0.0% |
| 2020 Q2 | 825 Million EUR | 0.0% |
| 2020 FY | 854 Million EUR | 9.49% |
| 2019 Q4 | 780 Million EUR | 0.0% |
| 2019 FY | 780 Million EUR | 20.56% |
| 2019 Q2 | 706 Million EUR | 0.0% |
| 2018 Q4 | 647 Million EUR | 0.0% |
| 2018 FY | 647 Million EUR | 8.38% |
| 2018 Q2 | 632 Million EUR | 0.0% |
| 2017 FY | 597 Million EUR | 3.29% |
| 2017 Q2 | 610 Million EUR | 0.0% |
| 2017 Q4 | 597 Million EUR | 0.0% |
| 2016 Q4 | 578 Million EUR | 0.0% |
| 2016 FY | 578 Million EUR | 2.12% |
| 2016 Q2 | 589 Million EUR | 0.0% |
| 2015 Q4 | 566 Million EUR | 0.0% |
| 2015 Q2 | 570 Million EUR | 0.0% |
| 2015 FY | 566 Million EUR | 3.47% |
| 2014 Q2 | 625 Million EUR | 0.0% |
| 2014 FY | 547 Million EUR | -12.76% |
| 2014 Q4 | 547 Million EUR | 0.0% |
| 2013 Q4 | 627 Million EUR | 0.0% |
| 2013 FY | 627 Million EUR | 1.79% |
| 2013 Q2 | 647 Million EUR | 0.0% |
| 2012 Q2 | 600 Million EUR | 0.0% |
| 2012 FY | 616 Million EUR | 14.71% |
| 2012 Q4 | 616 Million EUR | 0.0% |
| 2011 Q4 | 537 Million EUR | 0.0% |
| 2011 Q2 | 436 Million EUR | 0.0% |
| 2011 FY | 537 Million EUR | 23.73% |
| 2010 FY | 434 Million EUR | 7.16% |
| 2010 Q4 | 434 Million EUR | 0.0% |
| 2010 Q2 | 412 Million EUR | 0.0% |
| 2009 Q4 | 405 Million EUR | 0.0% |
| 2009 FY | 405 Million EUR | 11.57% |
| 2008 FY | 363 Million EUR | 18.24% |
| 2007 FY | 307 Million EUR | -28.94% |
| 2006 FY | 432 Million EUR | 65.52% |
| 2005 FY | 261 Million EUR | -30.78% |
| 2004 FY | 377.05 Million EUR | -6.66% |
| 2003 FY | 403.94 Million EUR | -47.77% |
| 2002 FY | 773.43 Million EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -466415.837% |
| ABIVAX Société Anonyme | 1.00 EUR | -103099999900.0% |
| Adocia SA | 272 Thousand EUR | -378944.118% |
| Aelis Farma SA | 53 Thousand EUR | -1945183.019% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | -59118.84% |
| genOway Société anonyme | 982.75 Thousand EUR | -104809.585% |
| IntegraGen SA | 311.44 Thousand EUR | -330933.331% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -626183.243% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 93095.483% |
| Plant Advanced Technologies SA | 1.22 Million EUR | -84093.3% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 865207.069% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -1132867.033% |
| Valbiotis SA | 1 Million EUR | -102487.167% |
| TheraVet SA | 123.34 Thousand EUR | -835787.208% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -103099999900.0% |
| argenx SE | 281.12 Million EUR | -266.735% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | -81725.397% |
| DBV Technologies S.A. | 1.00 USD | -103099999900.0% |
| Galapagos NV | 73.97 Million EUR | -1293.658% |
| Genfit S.A. | 4000.00 EUR | -25774900.0% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -103099999900.0% |
| Innate Pharma S.A. | 1.00 EUR | -103099999900.0% |
| Inventiva S.A. | 417 Thousand EUR | -247142.206% |
| MaaT Pharma SA | 190 Thousand EUR | -542531.579% |
| MedinCell S.A. | -6.71 Million EUR | 15455.973% |
| Nanobiotix S.A. | 200 Thousand EUR | -515400.0% |
| Onward Medical N.V. | 936 Thousand EUR | -110049.573% |
| Oryzon Genomics S.A. | 6029.00 EUR | -17100580.046% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -805368.75% |
| Pharming Group N.V. | 51.38 Million EUR | -1906.508% |
| Poxel S.A. | 2.95 Million EUR | -34778.214% |
| GenSight Biologics S.A. | 1.00 EUR | -103099999900.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| Valneva SE | 44.46 Million EUR | -2218.625% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -103099999900.0% |